# 7-Hydroxymitragynine and Nicotine Pouch Withdrawal Syndrome: A Case Report

**Authors:** Akshay Sharma, Beena S Nair, Sudhakar Pemminati

PMC · DOI: 10.7759/cureus.98386 · Cureus · 2025-12-03

## TL;DR

A patient experienced severe withdrawal symptoms from kratom and nicotine pouches, requiring intensive care and highlighting the challenges of managing novel psychoactive substance withdrawal.

## Contribution

This case report documents the severe and complex withdrawal syndrome from 7-hydroxymitragynine and nicotine pouches, emphasizing clinical management challenges.

## Key findings

- The patient exhibited overlapping opioid-like and nicotinic withdrawal symptoms leading to severe agitation and psychosis.
- Failed outpatient management and complications with buprenorphine initiation were observed.
- The case underscores the need for multidisciplinary approaches in managing withdrawal from novel psychoactive substances.

## Abstract

Novel psychoactive substances (NPSs) such as kratom and oral nicotine pouches present new challenges in clinical management, particularly regarding dependence and withdrawal. We report a case of severe withdrawal from concentrated 7-hydroxymitragynine (7-OH), a potent kratom alkaloid, and high-dose oral nicotine pouches, following long-term use in a patient with a history of polysubstance use. The patient developed acute, overlapping opioid-like (insomnia, myalgia, anxiety, diaphoresis, and gastrointestinal upset) and nicotinic (intense craving, irritability, restlessness, and difficulty concentrating) withdrawal symptoms. These symptoms rapidly escalated to severe agitation, psychosis, and respiratory compromise requiring intubation and intensive care. The clinical course was further complicated by failed outpatient management, precipitated withdrawal after initiation of buprenorphine, and eventual discharge against medical advice (AMA). This case report highlights the diagnostic and therapeutic complexities of managing withdrawal from novel psychoactive substances, the need for multidisciplinary and flexible approaches, and the importance of systematic assessment and harm reduction as these products become increasingly prevalent.

## Linked entities

- **Chemicals:** 7-hydroxymitragynine (PubChem CID 44301524), buprenorphine (PubChem CID 644073)

## Full-text entities

- **Diseases:** respiratory compromise (MESH:D012131), gastrointestinal upset (MESH:D005767), irritability (MESH:D001523), Nicotine Pouch Withdrawal Syndrome (MESH:D014029), craving (MESH:C564883), withdrawal (MESH:D013375), psychosis (MESH:D011618), insomnia (MESH:D007319), agitation (MESH:D011595), difficulty concentrating (MESH:C567712), myalgia (MESH:D063806), anxiety (MESH:D001007)
- **Chemicals:** buprenorphine (MESH:D002047), nicotine (MESH:D009538), 7-OH (-), 7-Hydroxymitragynine (MESH:C482678), kratom alkaloid (MESH:C001801)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12758578/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12758578/full.md

---
Source: https://tomesphere.com/paper/PMC12758578